leo: resolve merge conflict — apply GLP-1 lifestyle modification enrichments to post-restructure main
- What: Cherry-picked lifestyle+exercise enrichments, resolved conflicts with WHO GLP-1 enrichments (both kept) - Why: Epimetheus archive restructure + parallel WHO enrichment merge caused conflicts Pentagon-Agent: Leo <A3DC172B-F0A4-4408-9E3B-CF842616AAE1>
This commit is contained in:
parent
25a2bcf36e
commit
c630c34e3e
4 changed files with 49 additions and 1 deletions
|
|
@ -89,6 +89,11 @@ BALANCE Model's dual payment mechanism (capitation adjustment + reinsurance) plu
|
|||
|
||||
WHO's conditional recommendation structure and behavioral therapy requirement suggest the 'chronic use model' framing may be incomplete. The guideline establishes medication-plus-behavioral-therapy as the standard, not medication alone, which may have different economics than the pure pharmaceutical model. WHO also announced it will develop 'an evidence-based prioritization framework to identify which adults with obesity should be prioritized for GLP-1 treatment'—implying targeted use rather than universal chronic treatment.
|
||||
|
||||
### Additional Evidence (challenge)
|
||||
*Source: [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]] | Added: 2026-03-18*
|
||||
|
||||
If GLP-1+exercise creates durable behavioral change that persists after medication stops (3.5kg regain vs 8.7kg for medication alone), then the chronic use assumption may be wrong. The optimal economic model might be time-limited GLP-1 as a catalyst for behavior change, not lifetime medication. This would dramatically reduce the inflationary cost trajectory if lifestyle support infrastructure can scale.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -77,6 +77,11 @@ BALANCE Model's manufacturer-funded lifestyle support requirement directly addre
|
|||
|
||||
WHO's conditional recommendation requiring behavioral therapy combination provides international regulatory support for adherence interventions. The guideline explicitly states GLP-1s should be 'combined with intensive behavioral therapy to maximize and sustain benefits'—directly addressing the persistence problem by making behavioral support the standard of care rather than an optional add-on.
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]] | Added: 2026-03-18*
|
||||
|
||||
Weight regain data shows that even among patients who complete treatment courses, GLP-1 alone produces 8.7kg regain vs 3.5kg for GLP-1+exercise by week 104 post-discontinuation. This means the persistence problem has two layers: patients stop taking the drug (15% continuation at 2 years), AND those who complete treatment cycles regain weight unless exercise is part of the intervention. The economic model must account for both discontinuation losses and post-treatment regain.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -0,0 +1,25 @@
|
|||
{
|
||||
"rejected_claims": [
|
||||
{
|
||||
"filename": "glp-1-combined-with-structured-exercise-achieves-substantially-better-weight-maintenance-than-medication-alone-suggesting-behavioral-change-outlasts-pharmacotherapy.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
}
|
||||
],
|
||||
"validation_stats": {
|
||||
"total": 1,
|
||||
"kept": 0,
|
||||
"fixed": 2,
|
||||
"rejected": 1,
|
||||
"fixes_applied": [
|
||||
"glp-1-combined-with-structured-exercise-achieves-substantially-better-weight-maintenance-than-medication-alone-suggesting-behavioral-change-outlasts-pharmacotherapy.md:set_created:2026-03-18",
|
||||
"glp-1-combined-with-structured-exercise-achieves-substantially-better-weight-maintenance-than-medication-alone-suggesting-behavioral-change-outlasts-pharmacotherapy.md:stripped_wiki_link:glp-1-persistence-drops-to-15-percent-at-two-years-for-non-d"
|
||||
],
|
||||
"rejections": [
|
||||
"glp-1-combined-with-structured-exercise-achieves-substantially-better-weight-maintenance-than-medication-alone-suggesting-behavioral-change-outlasts-pharmacotherapy.md:missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
"model": "anthropic/claude-sonnet-4.5",
|
||||
"date": "2026-03-18"
|
||||
}
|
||||
|
|
@ -7,9 +7,13 @@ date: 2026-03-01
|
|||
domain: health
|
||||
secondary_domains: []
|
||||
format: review
|
||||
status: unprocessed
|
||||
status: enrichment
|
||||
priority: high
|
||||
tags: [glp-1, lifestyle-modification, exercise, sarcopenia, muscle-preservation, adherence, weight-regain, obesity]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-18
|
||||
enrichments_applied: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
|
@ -75,3 +79,12 @@ Synthesis of 2025-2026 research on combining lifestyle modifications (diet, exer
|
|||
PRIMARY CONNECTION: GLP-1 cost-effectiveness under capitation requires solving the adherence paradox (March 12 claim candidate)
|
||||
WHY ARCHIVED: The "exercise is the active ingredient for weight maintenance" finding significantly changes how to evaluate BALANCE model design and GLP-1 economic models under VBC
|
||||
EXTRACTION HINT: Focus on the GLP-1 alone vs. GLP-1+exercise regain comparison — this is the claim-worthy finding. Also note the BALANCE model design needs evaluation against this evidence.
|
||||
|
||||
|
||||
## Key Facts
|
||||
- WHO December 2025 guidelines recommend GLP-1 therapies 'combined with intensive behavioral therapy to maximize and sustain benefits'
|
||||
- Meta-analysis of 22 RCTs with 2,258 participants found ~25% of GLP-1 weight loss is lean mass
|
||||
- Without exercise, 15-40% of GLP-1 weight loss is lean mass; with resistance training, lean mass loss is substantially reduced
|
||||
- Up to half of adults over 80 experience sarcopenia; aging reduces muscle mass 12-16% baseline
|
||||
- Tirzepatide may have better muscle preservation profile than semaglutide (preliminary data)
|
||||
- No FDA-approved GLP-1 compounds with proven muscle preservation claims yet
|
||||
|
|
|
|||
Loading…
Reference in a new issue